医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces License of PDPS Technology to Lilly

2016年03月07日 PM04:45
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a Technology License Agreement with U.S.-based Eli Lilly and Company (Lilly, NYSE: LLY) to nonexclusively license PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive upfront and annual technology access payments, and will be eligible to receive development milestones and royalties on future sales of products (both peptide and small molecule therapeutics) that arise from use of the PDPS technology. Similar to previous technology licenses, the license will exclude work on peptide-drug conjugate (PDC) programs, as PeptiDream has extensive internal development efforts ongoing in this area, to which PeptiDream will be providing additional information soon.

PeptiDream will continue to work with Lilly to identify and develop potential drug candidates for Lilly’s targets using PeptiDream’s PDPS technology, under the original agreement in December 2013, in addition to the technology transfer. PeptiDream is eligible to receive milestone payments upon the successful achievement of certain development milestones and royalties on future sales of products that arise from the agreements. Further financial terms have not been disclosed.

In the past six years, PeptiDream has established funded discovery collaborations with 15 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, and Shionogi, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, and Lilly.

[Comment from Kiichi Kubota, President & CEO of PeptiDream Inc]

We are delighted that Lilly has decided to internalize our PDPS technology. Our PDPS technology aims to target sites not identified by conventional methods, which can then serve as the starting point for the development of either peptide or small molecule based therapeutics. The license with Lilly is a testament to how PDPS technology is changing the way drugs are discovered.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160306005056/en/

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com
http://www.peptidream.com/en/

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 国际纳米技术展览暨研讨会——2017纳米科技展将为您带来尖端技术与材料的最新资讯,令超智能社会触手可及
  • Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
  • Bioventus选择MEDSERVICE作为DUROLANE®在俄罗斯的经销商
  • “nano tech 2017 国際ナノテクノロジー総合展・技術会議”開催、超スマート社会の実現に貢献する最先端技術・材料の最新情報を発信!
  • nano tech 2017, the International Nanotechnology Exhibition & Conference, Brings You the Latest Information on the Cutting Edge Technologies and Materials Making the Super Smart Society a Reality